Integrated BioPharma, Inc. reported earnings results for the second quarter and six months ended December 31, 2023. For the second quarter, the company reported sales was USD 11.51 million compared to USD 12.25 million a year ago. Net loss was USD 0.382 million compared to USD 0.055 million a year ago. Basic loss per share from continuing operations was USD 0.01.
For the six months, sales was USD 24.42 million compared to USD 24.58 million a year ago. Net loss was USD 0.441 million compared to USD 0.09 million a year ago. Basic loss per share from continuing operations was USD 0.02.